The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $32.28

Today's change+1.08 +3.46%
Updated August 24 1:00 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $32.28

Today's change+1.08 +3.46%
Updated August 24 1:00 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc Hits New 50-day High

Valeant Pharmaceuticals International Inc is up sharply today, rallying (U.S.)$1.08 or 3.46% to (U.S.)$32.28 and setting a new 50-day high. Over the last five days, shares have gained 7.60%, but are down 68.24% for the last year to date. Shares have underperformed the S&P 500 by 100.74% during the last year.

Key company metrics

  • Open(U.S.) $31.39
  • Previous close(U.S.) $31.20
  • High(U.S.) $32.75
  • Low(U.S.) $31.25
  • Bid / Ask(U.S.) $32.28 / (U.S.) $32.29
  • YTD % change-68.24%
  • Volume24,659,705
  • Average volume (10-day)43,634,322
  • Average volume (1-month)31,589,408
  • Average volume (3-month)30,469,733
  • 52-week range(U.S.) $18.55 to (U.S.) $245.82
  • Beta0.08
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward4.77×
  • Forward PEG0.39×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.86
Updated August 24 1:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.39%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2016Q1/2016Q4/2015Q3/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015
Revenue2,4202,3722,7362,787
Total other revenue--------
Total revenue2,4202,3722,7362,787
Gross profit1,7621,7422,0602,139
Total cost of revenue658630677648
Total operating expense2,3402,3052,5422,339
Selling / general / administrative672813743698
Research & development12410396102
Depreciation / amortization888695789679
Interest expense (income), net operating--------
Unusual expense (income)4442195182
Other operating expenses, total-45234330
Operating income8166195448
Interest income (expense), net non-operating-473-427-433-420
Gain (loss) on sale of assets--------
Other--------
Income before tax-377-366-240-6
Income after tax-304-373-36252
Income tax, total-737122-57
Net income-302-374-36250
Total adjustments to net income--------
Net income before extra. items-302-374-36250
Minority interest2-11-2
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-302-374-36250
Inc. avail. to common incl. extra. items-302-374-36250
Diluted net income-302-374-36250
Dilution adjustment0----0
Diluted weighted average shares345345348351
Diluted EPS excluding extraordinary itemsvalue per share-0.88-1.08-1.040.14
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.78-1.00-0.540.57